Collaborations and partners
Collaborations with partners is key to our success. Great scientific breakthroughs often happen through collaborations between industry and academia. Working with world-renowned research centers and clinics can provide vital access to patient samples and data as well as crucial clinical expertise. We also highly value our close links with Key Opinion Leaders and patient organizations as they provide important insight, know-how and means to affect change.
Research centers and clinics
To get access to a broad patient base and ongoing screening programs in pancreatic cancer, we have started collaborations with research centers and clinics with world-renowned expertise, including Mount Sinai, New York; Knight Cancer Institute at Oregon Health and Sciences University, Portland, OR; The University of Pittsburgh Medical Center Pittsburgh, PA; University of Michigan, MI; The Massachusetts General Hospital, Boston, MA; NYU School of Medicine, New York; Research Institute of the McGill University Health Centre (RI-MUHC), Montreal Canada; The Trustees of the University of Pennsylvania; University of Massachusetts; Yale University MA; The University of Liverpool, UK; Ramon y Cajal Institute for Health Research Madrid, Spain; University Hospital of Santiago de Compostela, Spain, Clínica Universidad de Navarra, Spain, Catalan Institute of Oncology (ICO Hospitalet) – Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain, Karolinska Institutet, Stockholm, Sweden, Sahlgrenska University Hospital, Gothenburg, Sweden, Umeå University Hospital, Sweden and Linköping University Hospital, Sweden.
Advisory board with Key Opinion Leaders
Immunovia has formed a Scientific Advisory Board consisting of Key Opinion Leaders (KOL) worldwide that provide expertise and can influence medical practice and national guidelines.
The National Cancer Institute, US
In 2017, a memorandum of understanding with the National Cancer Institute (NCI), was signed with the ambition to work within a consortium of 12 major health care systems providing patient samples from up to 10,000 diabetes patients over 3 years. The company is pursuing similar schemes in order set up prospective studies among diabetes risk groups as quickly as possible and eventually receive reimbursement and national guideline status.
To ensure the introduction of IMMray™ PanCan-d into clinical practice, close collaboration with patient organizations is crucial. Collaboration continues with the Pancreatic Cancer Action Network or PanCAN, the largest US-based patient organization, which during 2016 formed a world coalition of more than 50 pancreatic cancer patient organizations. Immunovia joined World Pancreatic Cancer Coalition (WPCC) in May 2016.